Paper Details

  1. Home
  2. Paper Details

Comparison of miglitol and glibenclamide in diet-treated type 2 diabetic patients.

Author: BozzaM, Corgiat-MansinL, CraveroF, GiordaC, MarenaS, PaganoG, RossiC M

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Controlled Clinical TrialA clinical trial that evaluates the effectiveness of a treatment by comparing a group that receives the intervention with a group that receives a placebo or standard treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Miglitol, an intestinal alpha-glucosidase inhibitor, was effective in reducing HbA1c levels in patients with type 2 diabetes. Miglitol was comparable to glibenclamide in efficacy, but had fewer side effects. Both drugs were well tolerated.
Paper Details　
Original Abstract of the Article :
The efficacy of the new intestinal alpha-glucosidase inhibitor, miglitol, and glibenclamide were compared in a 6-month double-blind controlled protocol involving 100 non-insulin dependent diabetic patients under diet alone. HbA1c levels (initially between 7 and 11%) were reduced (p < 0.05): -0.78 +/...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/7556806

データ提供：米国国立医学図書館（NLM）

Miglitol vs. Glibenclamide for Type 2 Diabetes: A Comparative Study

The management of type 2 diabetes can be likened to navigating a delicate balance in the desert. This study compares the effectiveness of two medications, miglitol and glibenclamide, in managing type 2 diabetes in patients already following a dietary plan. It's like exploring different methods of irrigation in the desert, finding the most effective way to sustain life.

The study found that both medications were effective in reducing HbA1c levels. However, glibenclamide appeared to be more effective at 8 and 16 weeks. Miglitol showed similar effectiveness but over a longer duration. This highlights the importance of finding the right medication and dosage for each individual.

Miglitol and Glibenclamide: Finding the Right Fit for Diabetes Management

This study demonstrates that both miglitol and glibenclamide can be effective in managing type 2 diabetes in patients who are already following a dietary plan. The study also suggests that glibenclamide may provide a faster initial response, while miglitol may offer more sustained effectiveness.

Type 2 Diabetes: Personalized Management for Optimal Outcomes

This study underscores the need for personalized management strategies for type 2 diabetes. It's like recognizing that different desert plants require different amounts of water and sunlight to thrive. By working with a healthcare professional, individuals with type 2 diabetes can find the best medication and dosage to manage their condition and optimize their health outcomes.

Dr.Camel's Conclusion

This study offers valuable insights into the comparative effectiveness of miglitol and glibenclamide in managing type 2 diabetes. It's like having two different tools to manage a delicate ecosystem in the desert. Understanding the strengths and limitations of each medication can help individuals and their healthcare providers develop a personalized treatment plan that maximizes effectiveness and minimizes side effects.

Date :
  1. Date Completed 1995-11-03
  2. Date Revised 2022-12-07
Further Info :

Pubmed ID

7556806

DOI: Digital Object Identifier

7556806

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.